Get the Stockscreener App
6.98
1.75%
0.12
After Hours:
6.96
-0.02
-0.29%
Immunitybio Inc stock is traded at $6.98, with a volume of 16.46M.
It is up +1.75% in the last 24 hours and down -19.49% over the past month.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$6.86
Open:
$7.3
24h Volume:
16.46M
Relative Volume:
0.45
Market Cap:
$7.21B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-17.91
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-2.24%
1M Performance:
-19.49%
6M Performance:
+175.89%
1Y Performance:
+188.43%
1-Day Range:
$6.80
$7.42
1-Week Range:
$6.68
$7.63
52-Week Range:
$1.83
$12.43
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
6.98 | 7.08B | 113.29M | -351.47M | -309.19M | -0.3898 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
View All
Immunitybio Inc Stock (IBRX) Latest News
Kaplan Fox Alerts Investors of ImmunityBio, Inc. (IBRX) to a Securities Class Action Deadline on May 26, 2026 - NewMediaWire
IBRX INVESTOR REMINDER: ImmunityBio, Inc. Investors Have Until May 26, 2026 To Seek Lead Plaintiff Role - Business Wire
IBRX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against ImmunityBio, Inc. (IBRX) And Encourages Shareholders to Reach Out - ACCESS Newswire
IBRX stock set to snap 2 days of losses? Anktiva back in focus ahead of COVID-cancer link data - MSN
IBRX Stock Set To Snap 2 Days Of Losses? Anktiva Back In Focus Ahead Of COVID-Cancer Link Data - Stocktwits
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Black Hills Pioneer
IBRX Stock In Spotlight As FDA Scrutiny Prompts ImmunityBio To Withdraw Content, Tighten Oversight - Stocktwits
ImmunityBio, Inc. Securities Fraud Class Action Result of - GlobeNewswire
ImmunityBio (IBRX) Stock Falls Following FDA Warning Letter ResponseNews and Statistics - IndexBox
ImmunityBio Filmmaker Traded On Insider Tip, SEC Says - Law360
STLA INVESTOR ALERT: Stellantis N.V. Investors with Substantial Losses Have Opportunity to Lead the Stellantis Class Action Lawsuit – RGRD Law - GlobeNewswire Inc.
IBRX Investor Alert: ImmunityBio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Chairman Allegedly Misbranded Cancer Drug - marketscreener.com
ROSEN, THE FIRST FILING FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Actio - GuruFocus
Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who - GlobeNewswire
IBRX Shareholder Alert: ImmunityBio, Inc. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law Firm - Morningstar
IBRX Responds to FDA Warning Over Misleading Cancer Drug Claims - Yahoo Finance UK
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Is ImmunityBio’s (IBRX) FDA Promotion Setback Reframing the Stock’s Risk and Credibility Narrative? - Yahoo Finance
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm - Morningstar
Why ImmunityBio Stock Slumped on Monday - AOL.com
ImmunityBio, Inc. (IBRX) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - The Globe and Mail
ImmunityBio (IBRX) Faces FDA Warning, BTIG Stays Positive - Insider Monkey
FDA warns company over cancer drug claims - Santa Clarita Valley Signal
ImmunityBio And 2 Insider Picks For Promising Growth - simplywall.st
FDA issues warning letter to ImmunityBio over misleading promotion of NAI - Urology Times
IBRX stock in spotlight as FDA scrutiny prompts ImmunityBio to withdraw content, tighten oversight - MSN
ImmunityBio Addresses FDA Concerns on Promotional Materials, Enhances Compliance Measures for ANKTIVA® 1 - Minichart
IBRX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 - marketscreener.com
ImmunityBio Addresses FDA Warning on ANKTIVA Promotion - TipRanks
Immunity Bio responds to FDA concerns over Anktiva marketing materials - Seeking Alpha
ImmunityBio responds to FDA promotional compliance concerns - Investing.com
ImmunityBio (IBRX) Stock Gains 3% Following FDA Compliance Response on Anktiva Marketing - Blockonomi
ImmunityBio submits response to FDA OPDP, removes podcast and strengthens promotional compliance - TradingView
ImmunityBio responds to FDA promotional compliance concerns By Investing.com - in.investing.com
ImmunityBio (NASDAQ: IBRX) outlines response to FDA ad concerns - Stock Titan
ImmunityBio (IBRX) Stock Climbs 3% After Firing Back at FDA Over Anktiva Ad Concerns - coincentral.com
Jim Cramer on ImmunityBio: "That stock is part of the magical thinking era" - MSN
ImmunityBio stock rises after FDA compliance response By Investing.com - Investing.com Canada
ImmunityBio stock rises after FDA compliance response - Investing.com
ImmunityBio addresses FDA correspondence and reaffirms commitment to advertising compliance - marketscreener.com
Immunitybio Addresses FDA Correspondence And Reaffirms Commitment To Advertising Compliance - tradingview.com
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance - Business Wire
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Deadline in Securities Fraud Class Action Lawsuit - FinancialContent
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - WBOC TV
Securing Non-Dilutive Funding to Support Immunotherapy Platform Growth – ImmunityBio - Oncodaily
CG Oncology: Passing A Red Line For What I Would Call A Reasonable Valuation (Downgrade) - Seeking Alpha
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
1.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):